Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma - 24/04/13
Abstract |
Background |
Merkel cell polyomavirus (MCV) was discovered by digital transcriptome subtraction as a monoclonal infection of Merkel cell carcinoma (MCC) tumors. Subsequent studies have repeatedly confirmed that MCV is the likely cause for most MCC. Polymerase chain reaction–based detection of the virus in other nonmelanoma skin cancers, however, has been inconsistent and controversial.
Objective |
We sought to directly assay for MCV infection in squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) tumor cells by immunostaining for viral antigen.
Methods |
CM2B4, a monoclonal antibody to exon 2 peptides of MCV T antigen, was used to examine tumors from 20 patients with MCC with and without secondary SCC or BCC tumors.
Results |
MCV T antigen was readily detected in 15 (75%) of 20 MCC tumors including 11 MCC tumors from patients with secondary SCC or BCC. In contrast to MCC, none of these secondary BCC or SCC was MCV T-antigen positive.
Limitations |
A limitation was the small study size with antigen detection including only the MCV large T and 57kT proteins.
Conclusions |
MCV T antigen is generally not expressed in BCC or SCC tumors from a population favored to have MCV infection, ie, those persons already given the diagnosis of MCV-positive MCC. This suggests that episodic polymerase chain reaction detection of MCV genome in BCC or SCC tumors may represent coincidental rather than causal infection, and that these tumors share other noninfectious risk factors.
Le texte complet de cet article est disponible en PDF.Key words : basal cell carcinoma, CM2B4, Merkel cell polyomavirus, squamous cell carcinoma, T antigen
Abbreviations used : BCC, MCC, MCV, PCR, SCC
Plan
Supported by National Institutes of HealthCA136363, CA120726; Al Copeland Foundation; University of Pittsburgh EXPLORER grant; and American Cancer Society Professorship Grants to Drs Chang and Moore. |
|
Disclosure: The University of Pittsburgh has submitted patents that may be related to this work. |
Vol 63 - N° 3
P. 400-403 - septembre 2010 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?